BIOVAXYS TECHNOLOGY CORP - BVAXF STOCK NEWS

BioVaxys Technology Corp. (BVAXF) and SpayVac-for-Wildlife, Inc. have announced a trial to test SpayVac®, a long-lasting, single-dose contraceptive vaccine, in captive Asian elephants. The trial, conducted in partnership with Chiang Mai University in Thailand, aims to address concerns about human-elephant conflicts and ecological impacts due to confined elephant populations. SpayVac utilizes BioVaxys' patented liposome-based antigen delivery platform, which has shown sustained immune responses in various species.

The research, which began in April, will track reproductive cycling, contraceptive efficacy, and antibody titers over a 5-year period. A previous trial with African elephants demonstrated elevated antibody titers for at least 7 years after a single dose. SpayVac is also planning to commercialize fertility control vaccines for other animals using the same technology.

BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTC: BVAXF) announced the revocation of a cease trade order issued by the Ontario Securities Commission (OSC) on May 15, 2024. The order was due to delays in filing audited annual financial statements for the year ended October 31, 2023, and interim financial statements for the three months ended January 31, 2024. The company has now completed these filings, along with interim financial statements for the six months ended April 30, 2024. The OSC confirmed the order revocation on July 11, 2024, with all filings available on SEDAR+.

BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) has been issued a Failure-to-File Cease Trade Order (FFCTO) by the Ontario Securities Commission (OSC) due to delays in filing required financial statements and discussions for the fiscal year ending October 31, 2023, and the three months ending January 31, 2024. The FFCTO, effective May 15, 2024, prohibits any trading of BioVaxys securities in Canada. The company missed deadlines of February 28, 2024, for annual filings and April 1, 2024, for interim filings. They are working to complete these filings soon and expect the FFCTO to be lifted once compliance is achieved.

BioVaxys Technology Corp. appoints Christopher Cherry as Chief Financial Officer, bringing extensive experience in financial management. The company anticipates significant growth following the recent acquisition of IMV Intellectual Property.

BioVaxys Technology Corp. is providing a bi-weekly update on the status of the management cease trade order (MCTO) granted by the Ontario Securities Commission. The delay in filing required financial statements is due to the auditor needing more time to complete the audit. The MCTO extension has been granted until May 13, 2024, to allow for the completion of the audit related to the recent acquisition of assets from IMV Inc.

BioVaxys Technology Corp. and SpayVac-for-Wildlife, Inc. announce a partnership to field test immuno-contraceptive vaccines in farmed rainbow trout. The technology aims to manage challenges in aquaculture industry and prevent breeding with wild fish. Initial trials show promising results, with plans to expand to other animal species.

BioVaxys Technology Corp. receives a Notice of Allowance from the USPTO for a Patent on inducing an antibody immune response using low dose volume delivery of a B-cell epitope formulated with DPX™. The company's proprietary lipid-based delivery platform DPX™ shows promise for cancer immunotherapeutics and therapeutic vaccines.

BioVaxys Technology Corp. announced that the Ontario Securities Commission granted a management cease trade order due to delayed financial filings. The delay was caused by additional information needed for audits and recent acquisitions. The Company expects to file the Required Reports within 30 days of the original deadline.

BioVaxys Technology Corp. receives a Notice of Allowance from the Japanese Patent Office for a Patent related to inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. The DPX™ platform attracts antigen presenting cells to the injection site, enhancing immune response. BioVaxys also files an international patent application for methods of formulating DPX™ compositions with lipid-based and polynucleotide adjuvants.